“Pharmacoeconomic Comparison of Ziprasidone With Other Atypical Oral Antipsychotic Agents in Schizophrenia”. Farmeconomia. Health Economics and Therapeutic Pathways, vol. 12, no. 1, Nov. 2011, pp. 29-40, https://doi.org/10.7175/fe.v12i1.96.